Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Lee, Stephanie J.; Kukreja, Manisha; Wang, Tao; Giralt, Sergío; Szer, Jeffrey; Arora, Mukta; Woolfrey, Ann E.; Cervantes, Francisco; Champlin, Richard E.; Gale, Robert Peter; Halter, Joerg; Keating, Armand; Marks, David I.; McCarthy, Philip L.; Olavarría, Eduardo; Stadtmauer, Edward A.; Abecasis, Manuel; Gupta, Vikas; Khoury, H. Jean; George, Biju; Hale, Gregory A.; Liesveld, Jane L.; Rizzieri, David A.; Antin, Joseph H.; Bolwell, Brian J.; Carabasi, Matthew; Copelan, Edward A.; İlhan, Osman; Litzow, Mark R.; Schouten, H; Zander, Axel R.; Horowitz, Mary M.; Maziarz, Richard T.

doi:10.1182/blood-2008-02-141689

Cited by 125 publications

(91 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated that prior therapy with imatinib not only does not adversely affect the outcome of patients who undergo allogeneic SCT, but it actually may improve survival after transplantation for those who undergo transplantation in first CP. 27 Similarly, it has been reported that previous exposure to a second-generation TKI did not increase transplantation-related toxicity or the risk thereof. 28 Although the published experience is limited, it has been demonstrated that SCT is effective in the setting of ABL kinase domain mutations.…”

Section: Discussionmentioning

confidence: 99%

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR‐ABL kinase domain mutation T315I

Velev

Cortes

Champlin

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND: Resistance to tyrosine kinase inhibitor (TKIs) therapy is associated with the development of kinase domain mutations. Although many imatinib-resistant mutations respond well to second-generation TKIs, the threonine-to-isoleucine mutation at codon 315 of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion Bcr-Abl (T315I) is insensitive to all currently available TKIs. The outcome in such patients after stem cell transplantation (SCT) is unknown. METHODS: Eight patients with TKI-resistant CML who had T315I mutations underwent 9 transplantations. At the time of SCT, 2 patients were in chronic phase, 3 patients were in accelerated phase; and 3 patients were in second chronic phase. RESULTS: The best responses after SCT were a complete molecular response (CMR) in 3 patients, a complete cytogenetic response (CCyR) in 4 patients, and a complete hematologic response (CHR) in 1 patient, and 1 patient had no response. The best outcome was for patients who underwent transplantation in chronic phase, and both of those patients remained alive and in complete molecular remission 14 months and 42 months after SCT. After a median follow-up of 13 months from SCT, 5 patients remained alive, including 3 patients in CMR, 1 patient in CCyR, and 1 patient in CHR. CONCLUSIONS: The current results indicated that SCT is an effective strategy for patients with CML who have the T315I mutation, particularly in earlier stages. Cancer 2010;116;3631-7.

show abstract

Section: Discussionmentioning

confidence: 99%

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR‐ABL kinase domain mutation T315I

Velev

Cortes

Champlin

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…Lee et al analyzed 216 IM + and 216 IM -allograft recipients with advanced-phase CML suggested that the use of imatinib before HSCT was not associated with treatmentrelated mortality, relapse, leukemia-free survival or overall survival [9].…”

Section: Discussionmentioning

confidence: 99%

Second Generation Tyrosine Kinase Inhibitors Combined With Allogeneic Hematopoietic Stem Cell Transplantation Improve the Prognosis of Patients with Chronic Myelogenous Leukemia in Blast Crisis

Yu¹,

Ding²,

Sun³

et al. 2017

J Stem Cell Res Ther

View full text Add to dashboard Cite

“…11 The 3-year OS was 72% vs 65% (P = 0.07) in patients with prior TKI vs no TKI, suggesting that transplant outcomes were not compromised by the use of drug therapy before transplantation. 11 The German CML group published an interim analysis of patients who were transplanted early for high-risk disease, those who had failed imatinib and those who had advanced disease. A total of 84 patients received an allogeneic transplantation.…”

Section: Introductionmentioning

confidence: 99%

“…6 Before the approval of imatinib, CML was the most common indication for AHPCT in the first chronic phase, with an OS of 50% at 10 years. 7 11 showed, on 1309 patients (409 treated with imatinib before transplant), that patients who had received a TKI before undergoing an allogeneic transplant did not have worse outcomes. 11 The 3-year OS was 72% vs 65% (P = 0.07) in patients with prior TKI vs no TKI, suggesting that transplant outcomes were not compromised by the use of drug therapy before transplantation.…”

Section: Introductionmentioning

confidence: 99%

“…7 11 showed, on 1309 patients (409 treated with imatinib before transplant), that patients who had received a TKI before undergoing an allogeneic transplant did not have worse outcomes. 11 The 3-year OS was 72% vs 65% (P = 0.07) in patients with prior TKI vs no TKI, suggesting that transplant outcomes were not compromised by the use of drug therapy before transplantation. 11 The German CML group published an interim analysis of patients who were transplanted early for high-risk disease, those who had failed imatinib and those who had advanced disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors

Adekola

Popat

Ciurea

2014

Bone Marrow Transplant

View full text Add to dashboard Cite

Myeloproliferative neoplasms are a category of diseases that have been traditionally amenable to allogeneic hematopoietic progenitor cell transplantation. Current developments in drug therapy have delayed transplantation for more advanced phases of the disease, especially for patients with CML, whereas transplantation remains a mainstream treatment modality for patients with advanced myelofibrosis and chronic myelomonocytic leukemia. Reduced-intensity conditioning has decreased the treatmentrelated mortality, and advances in the use of alternative donors for transplantation could extend the use of this procedure to an increasing number of patients with improved safety and efficacy. Here we review the current knowledge about allogeneic transplantation for myeloproliferative neoplasms and discuss the most important aspects to be considered when contemplating transplantation for patients with these diseases. Janus kinase 2 inhibitors offer the promise to improve spleen size and performance of patients with myelofibrosis and extend transplantation for patients with more advanced disease.

show abstract

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Cited by 125 publications

References 23 publications

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR‐ABL kinase domain mutation T315I

Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR‐ABL kinase domain mutation T315I

Second Generation Tyrosine Kinase Inhibitors Combined With Allogeneic Hematopoietic Stem Cell Transplantation Improve the Prognosis of Patients with Chronic Myelogenous Leukemia in Blast Crisis

An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors

Contact Info

Product

Resources

About